Archives of Advances in Biosciences

Vol. 17 No. 1 (2026)

Phenotypic co-occurrence of resistance to aminoglycosides and fluoroquinolones in clinical isolates of Acinetobacter baumannii

Archives of Advances in Biosciences, Vol. 17 No. 1 (2026), 28 Ordibehesht 2026 , Page 1-6
https://doi.org/10.22037/aab.v17i1.51491

Abstract

Background and Aim: Acinetobacter baumannii is a major nosocomial pathogen associated with multidrug resistance, limiting therapeutic options in hospital settings. This study aimed to investigate antimicrobial susceptibility patterns and the co-occurrence of resistance to aminoglycosides and fluoroquinolones among clinical isolates of A. baumannii recovered from a tertiary hospital in Shahroud, Iran.

Methods: In this descriptive cross-sectional study, six non-duplicate clinical isolates of A. baumannii were collected from hospitalized patients. Species identification was confirmed by phenotypic methods and PCR detection of the intrinsic blaOXA-51-like gene. Antimicrobial susceptibility testing was performed using the Kirby–Bauer disk diffusion method and interpreted according to CLSI M100 (2024) guidelines. Data were analyzed descriptively, and hierarchical clustering was used for exploratory visualization of resistance patterns.

Results: All isolates (6/6, 100%) were classified as multidrug-resistant (MDR), and two isolates (2/6, 33.3%) met the criteria for extensively drug-resistant (XDR). All isolates (6/6, 100%) were resistant to ciprofloxacin. High resistance rates were observed among aminoglycosides, including amikacin (5/6, 83.3%), gentamicin (5/6, 83.3%), and tobramycin (5/6, 83.3%). Resistance to ceftazidime was observed in 5/6 isolates (83.3%), while resistance rates for cefepime, piperacillin–tazobactam, and ampicillin–sulbactam were 3/6 (50.0%) each. Resistance to carbapenems was detected in 4/6 isolates (66.7%) for meropenem and 3/6 (50.0%) for imipenem. Concurrent resistance to fluoroquinolones and aminoglycosides was observed across all isolates, indicating co-occurrence of resistance phenotypes.

Conclusion: The present study demonstrates a high burden of multidrug resistance and frequent co-occurrence of resistance to aminoglycosides and fluoroquinolones among clinical isolates of A. baumannii. These findings highlight the need for continued regional antimicrobial resistance surveillance and strengthened infection control strategies.

Keywords:
  • Acinetobacter baumannii
  • co resistance
  • aminoglycosides
  • fluoroquinolones
  • multidrug resistance

How to Cite

Abiri, E., Esfandiari, R., & Raesi, R. (2026). Phenotypic co-occurrence of resistance to aminoglycosides and fluoroquinolones in clinical isolates of Acinetobacter baumannii. Archives of Advances in Biosciences, 17(1), 1–6. https://doi.org/10.22037/aab.v17i1.51491

References

1. Gudueva E, Chemisova O. Pathogenicity factors of Acinetobacter baumannii. Med Vestn Yuga Ross. 2023;14(1):66-74. (LINK)

2. Ayoub Moubareck C, Hammoudi Halat D. Insights into Acinetobacter baumannii: a review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen. Antibiotics. 2020;9(3):119. (DOI: 10.3390/antibiotics9030119)

3. Li S, Jiang G, Wang S, Wang M, Wu Y, Zhang J, et al. Emergence and global spread of a dominant multidrug-resistant clade within Acinetobacter baumannii. Nat Commun. 2025;16(1):2787. (DOI: 10.1038/s41467-025-57896-y)

4. Dubey V, Reza N, Hope W. Drug-resistant Acinetobacter baumannii: mortality, emerging treatments, and future pharmacological targets for a WHO priority pathogen. Clin Microbiol Rev. 2025;38(3):e00279-24. (DOI: 10.1128/cmr.00279-24)

5. Sharma R, Lakhanpal D. Acinetobacter baumannii: A comprehensive review of global epidemiology, clinical implications, host interactions, mechanisms of antimicrobial resistance and mitigation strategies. Microb Pathog. 2025;204:107605. (DOI: 10.1016/j.micpath.2025.107605)

6. Zhang S, Di L, Qi Y, Qian X, Wang S. Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii. Front Cell Infect Microbiol. 2024;14:1395260. (DOI: 10.3389/fcimb.2024.1395260)

7. Kyriakidis I, Vasileiou E, Pana ZD, Tragiannidis A. Acinetobacter baumannii antibiotic resistance mechanisms. Pathogens. 2021;10(3):373. (DOI: 10.3390/pathogens10030373)

8. Scoffone VC, Trespidi G, Barbieri G, Arshad A, Israyilova A, Buroni S. The evolution of antimicrobial resistance in Acinetobacter baumannii and new strategies to fight it. Antibiotics. 2025;14(1):85. (DOI: 10.3390/antibiotics14010085)

9. Zack KM, Sorenson T, Joshi SG. Types and mechanisms of efflux pump systems and the potential of efflux pump inhibitors in the restoration of antimicrobial susceptibility, with a special reference to Acinetobacter baumannii. Pathogens. 2024;13(3):197. (DOI: 10.3390/pathogens13030197)

10. Abdi SN, Ghotaslou R, Ganbarov K, Mobed A, Tanomand A, Yousefi M, et al. Acinetobacter baumannii efflux pumps and antibiotic resistance. Infect Drug Resist. 2020;13:423-34. (DOI: 10.2147/IDR.S238260)

11. Xu C, Bilya S, Xu W. adeABC efflux gene in Acinetobacter baumannii. New Microbes New Infect. 2019;30:100549. (DOI: 10.1016/j.nmni.2019.100549)

12. Derakhshan Sefidi M, Heidary L, Shams S. Prevalence of imipenem-resistant Acinetobacter baumannii ISOLATES in Iran: A meta-analysis. Infect Epidemiol Microbiol. 2025;7(1):77-99. (DOI: 10.52547/iem.7.1.77)

13. Moradi J, Hashemi FB, Bahador A. Antibiotic resistance of Acinetobacter baumannii in Iran: a systemic review of the published literature. Osong Public Health Res Perspect. 2015;6(2):79-86. (DOI: 10.1016/j.phrp.2015.02.001)

14. Shakib P, Choolandaimy ZB, Rezaie F, Bahmani M, Delfani S. Systematic review and meta-analysis of carbapenem resistance of Acinetobacter baumannii in Iran. Infect Disord Drug Targets. 2020;20(5):611-9. (DOI: 10.2174/1871526519666191024161807)

15. Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas M, Giske C, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-81. (DOI: 10.1111/j.1469-0691.2011.03570.x)

16. Darby EM, Bavro VN, Dunn S, McNally A, Blair JM. RND pumps across the genus Acinetobacter: AdeIJK is the universal efflux pump. Microb Genom. 2023;9(3):000964. (DOI: 10.1099/mgen.0.000964)

17. Lee Y-T, Chen H-Y, Yang Y-S, Chou Y-C, Chang T-Y, Hsu W-J, et al. AdeABC efflux pump controlled by AdeRS two component system conferring resistance to tigecycline, omadacycline and eravacycline in clinical carbapenem resistant Acinetobacter nosocomialis. Front Microbiol. 2020;11:584789. (DOI: 10.3389/fmicb.2020.584789)

18. Mohammed MA, Salim MT, Anwer BE, Aboshanab KM, Aboulwafa MM. Impact of target site mutations and plasmid associated resistance genes acquisition on resistance of Acinetobacter baumannii to fluoroquinolones. Sci Rep. 2021;11(1):20136. (DOI: 10.1038/s41598-021-99572-8)

19. Rashvand P, Peymani A, Mohammadi M, Karami A, Samimi R, Hajian S, et al. Molecular survey of aminoglycoside-resistant Acinetobacter baumannii isolated from tertiary hospitals in Qazvin, Iran. ew Microbes New Infect. 2021;42:100883. (DOI: 10.1016/j.nmni.2021.100883)

20. Amirmozafari N, Haddadi A, Mirnejad R, Angaji SA, Babapour E. Association between drug efflux pumps and resistance to ciprofloxacin in clinical isolates of Acinetobacter baumannii. Iran J Med Microbiol. 2024;18(2):113-22. (DOI: 10.30699/ijmm.18.2.113)

21. Goudarzi H, Zarringhalam Moghaddam M, Kouchaki A, Hajizadeh M, Bandehpour M, Angoti G. Detection of efflux pump genes (adeA, adeB, adeC and abeM) in Acinetobacter baumannii isolated from hospitalize patients, North-west of Iran. Infect Epidemiol Microbiol. 2025;2(4):8-11. (DOI: 10.52547/iem.2.4.8)

22. Azimi L, Hasani H, Karimi A, Fahimzad A, Fallah F, Fatehi S, et al. Association Between Antibiotic Resistance Patterns and Analysis of Virulence Genes in Multi-drug Resistant Acinetobacter baumannii in Iran (2018). Arch Clin Infect Dis. 2025;20(20):e166009. (DOI: 10.5812/archcid-166009)

23. Maleki A, Kaviar VH, Koupaei M, Haddadi MH, Kalani BS, Valadbeigi H, et al. Molecular typing and antibiotic resistance patterns among clinical isolates of Acinetobacter baumannii recovered from burn patients in Tehran, Iran. Front Microbiol. 2022;13:994303. (DOI: 10.3389/fmicb.2022.994303)

24. Mostafavi SN, Rostami S, Nokhodian Z, Ataei B, Cheraghi A, Ataabadi P, et al. Antibacterial resistance patterns of Acinetobacter baumannii complex: The results of Isfahan antimicrobial resistance surveillance-1 program. Asian Pac J Trop Med. 2021;14(7):316-22. (DOI: 10.4103/1995-7645.321359)

25. Kazemian H, Karami‐Zarandi M, Heidari H, Ghanavati R, Khoshnood S. Antimicrobial combination effects against multidrug‐resistant Acinetobacter baumannii and Pseudomonas aeruginosa strains: A cross‐sectional study. Health Sci Rep. 2024;7(5):e2061. (DOI: 10.1002/hsr2.2061)

26. Liu J-H, Liu Y-Y, Shen Y-B, Yang J, Walsh TR, Wang Y, et al. Plasmid-mediated colistin-resistance genes: mcr. Trends Microbiol. 2024;32(4):365-78. (DOI: 10.1016/j.tim.2023.10.007)

27. Sadredinamin M, Yousefi NN, Pouladi I, Rezaei F, Delfani S. Prevalence of Mobile Colistin Resistance (mcr) Genes in Acinetobacter baumannii: Isolates of Clinical Infection from an Iranian University Hospital. Arch Clin Infect Dis. 2024;19(6):e148880. (DOI: 10.5812/archcid-148880)

28. Haeili M, Naghibi Biji SMR, Alsahlani F, Moghaddasi K, Omrani M, Ghodousi A, et al. Co-occurrence of plasmid-mediated colistin resistance gene, mcr-1 and bla CTX− M in multidrug-resistant Escherichia coli isolates from calves in Iran. Sci Rep. 2026 (In press). (LINK)

  • Abstract Viewed: 43 times
  • PDF Downloaded: 0 times

Download Statastics

Developed By

Open Journal Systems

Information